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INTRODUCTION
Phospholipid scramblase 1 (PLSCR1) is a member of a recently identified family of membrane proteins that has been proposed to contribute to the reorganization of plasma membrane phospholipids (PLs) in activated platelets and in injured or apoptotic cells exposed to elevated intracellular Ca 2+ . [1] [2] [3] In addition to a putative role in promoting transbilayer redistribution of plasma membrane PLs through this Ca 2+ -activated PL scramblase pathway, PLSCR1 has also been reported to be a substrate of several kinases that participate in cell proliferative, differentiation, or apoptotic responses, including protein kinase Cδ, c-Abl, and both IgE and EGF receptor-coupled kinase(s). [4] [5] [6] [7] Although suggested to play a role in the redistribution of plasma membrane PLs through the PL scramblase pathway, the actual cellular function(s) of PLSCR1 and related members of this gene family remains largely unresolved. The putative role of PLSCR1 in mediating Ca 2+ -dependent accelerated transbilayer migration of plasma membrane PLs derived from its capacity to mediate this function in reconstituted membrane systems, and the apparent correlation between levels of endogenous expression of cellular PLSCR1 and the propensity of various cells to expose phosphatidylserine (PS) in response to influx of Ca 2+ . 1, 2, 8 Subsequently, it was reported that the Thr-phosphorylation of PLSCR1 by cellular protein kinase Cδ served to promote surface exposure of plasma membrane PS in Jurkat cells induced to apoptosis, implicating a role for protein phosphorylation in activation of PLSCR1's PL-scrambling function. 4 Nevertheless, elevation of PLSCR1 expression by transfection was variably found to increase plasma membrane PL scramblase activity, 4, 8, 9 whereas no increase in such plasma membrane PL For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From scramblase activity was detected upon interferon-induced expression of PLSCR1, 10 or following Tyr-phosphorylation of PLSCR1 by activated c-Abl kinase. 6 The biologic significance of the phosphorylation of PLSCR1 by multiple cellular kinases also remains unclear. De novo expression of a mutant mRNA encoding a truncated form of murine PLSCR1 (deleting the proline-rich segment contained between codons 1-128) was identified in a monocytic leukemia cell line, and this mutation was found to correlate with the ability of these cells to proliferate in vivo. By contrast, expression of full-length PLSCR1 increased upon induced differentiation of these tumor cells to macrophages, suggesting that PLSCR1 might normally play some role in regulated cell growth and/or differentiation. 11 Furthermore, ectopic expression of recombinant human PLSCR1 in the HEY1B carcinoma cell line was found to markedly inhibit growth of solid tumors from these cells after subcutaneous transplantation. 12 Finally, in yeast, there is evidence that the single apparent PLSCR orthologue (YJR100C) is a stress-induced gene, 13 whereas human PLSCR1 expression is highly induced by the interferons, suggesting possible roles in immune/stress responses, cell cycle regulation, or apoptosis. 10, 14 In order to gain additional insight into what role PLSCR1 might play in the PL scramblase pathway and in cytokine-dependent cell growth and differentiation in vivo, we have investigated hematopoietic cell growth and differentiation in mice that are deficient in PLSCR1 due to homozygous disruption of the PLSCR1 gene locus. Whereas these mice display no apparent hematologic or hemostatic abnormality at steady state and their blood cells show normal PL scramblase activity, our results suggest that PLSCR1-/-hematopoietic precursor cells exhibit impaired proliferative and differentiation responses to select growth factors, in particular, stem cell factor (SCF) and granulocyte-stimulating factor (G-CSF).
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MATERIALS AND METHODS

Cytokines
Genotyping was performed by both Southern blotting and PCR of tail genomic DNA, and the absence of expressed protein in various cells and tissues of PLSCR1-/-mice was confirmed by Western blotting using monoclonal antibody 219.1 (reactive with murine and human PLSCR1) and affinity-purified rabbit antibody raised against murine PLSCR1 C-terminal and N-terminal peptides.
Southern blotting
Purified tail genomic DNA was digested with Xba I, separated on a 0.9% agarose gel, and transferred to a nylon membrane. PLSCR1 genomic DNA was detected by hybridization with a 32 P-labeled PLSCR1 DNA probe consisting of a 408 bp PLSCR1 genomic DNA fragment within the targeted region. Insertion of the targeting vector into the PLSCR1 locus shifts the detected Xba1-derived fragment of genomic DNA from 2.9 kb (wild-type) to 7.5 kb (knockout).
Northern blotting
Northern blotting was performed as previously described. 2, 15 In brief, total RNA from mouse kidney was resolved on a 1% denatured agarose gel and transferred to a nylon membrane. 
Western blotting
Cell lysates were mixed with sample buffer (50 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1% bromophenol blue) and heated at 100 
Blood collection and hematological profiles
For cell lineage analysis, RBC and platelet studies, and apoptosis assay, blood was collected by heart puncture and mixed 9:1 with 500 units/mL heparin. For analysis of G-CSF-induced granulocytosis, blood was collected by eye puncture using heparinized capillaries. Newborn mouse blood for blood cell counts was collected from a tail cut. Platelets and RBC were counted in a Coulter particle counter, and total white blood cell (WBC) counts were determined by hemacytometer. WBC differential counts were performed on a blood smear stained by Wright- 
Tail bleeding times
Mouse tail bleeding time was performed as described. 16 In brief, the tail was cut 2 mm from the end and immediately immersed into saline at 37 °C, and time to cessation of bleeding recorded.
Surface exposure of PS in RBC
Blood was collected by heart puncture, buffy coat removed by centrifugation, and the cells were 
Platelet activation
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Blood was collected by heart puncture. Platelets were isolated by centrifugation as described, 18 and suspended to 2x10 7 /mL in HEPES buffer (137 mM NaCl, 4mM KCl, 0.5 mM MgCl 2 , 1 mM CaCl 2 , 20 mM HEPES, pH 7.4) at 37°C. For measurement of cell surface-exposed PS or Pselectin, platelets (100 µL/tube) were incubated for 5 min in presence of ADP (10 µM) plus epinephrine (10 µM), collagen ( 10 µg/mL), α-thrombin (0.5 units/mL), α-thrombin (0.5 units/mL) plus collagen (10 µg/mL), or A23187 (1 µM). PS exposure was detected by the binding of factor Va as described for RBC above, and cell surface P-selectin with a FITC-labeled antibody specific for CD62p. For quantification of fibrinogen binding to platelets, FITC-labeled fibrinogen (20 µg/mL) was added prior to the addition of the agonists, except in the case of thrombin, which was first reacted with platelets followed by inhibition of the enzyme with hirudin (2.5 units/mL). Fibrinogen-containing samples were fixed with1% formaldehyde. All samples were additionally stained with biotinylated anti mouse CD41 as a platelet-specific marker, detected with phycoerythrin-labeled streptavidin (2.5 µg/mL). Single cell fluorescence was analyzed on a FACSCalibur, with acquisition gated on CD41-positive particles.
Cell isolation and culture
Mouse fetal livers were aseptically removed from embryos at day 15, and mechanically disrupted. The cells were suspended in RPMI, 10% FBS complete medium and passed through a 40 µm cell strainer (Becton Dickinson, Franklin Lakes, NJ) to remove aggregated cells. Spleens and thymuses were isolated from 6 to 8 week old mice, and cells were prepared as described for fetal liver. For bone marrow, femurs and tibia were removed from 6 to 8 week old mice. Bone marrow cells were flushed out and suspended in RPMI complete medium, and passed through a cell strainer.
Bone marrow cells (10 5 cells/mL) were first cultured for 6 days in T75 flasks in MethoCult 3234 (1% methylcellulose, 15% FBS, 1% bovine serum albumin, 10 µg/mL bovine pancreatic insulin, 200 µg/mL human transferrin, 100 µM β-mercaptoethanol, 2 mM glutamine in iMDM) supplemented with 10 ng/mL mouse IL-3 at the beginning of the culture. Thirty mL iMDM, 15%
FBS complete medium without cytokines were added to the flask, and the cells were cultured for another 4 days. Bone marrow progenitors formed large colonies, and all of the colonies were collected. The cells were harvested, washed with HBSS and used in subsequent culture in the presence of various cytokines.
Induction of PLSCR1 expression by cytokines
One million cultured bone marrow progenitor cells were mixed with 2 mL of MethoCult 3234, and either mouse SCF (20 ng/mL) or G-CSF (60 ng/mL) was added. The cells were incubated at 37 o C, 5% CO 2 for 3 days, harvested at different times during this period, washed twice with PBS, and lysed at 4 o C for 1h with cell lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 5mM EDTA, 1% Triton-X100, and Protease Inhibitor Cocktail). Cell lysates were centrifuged at 14,000 rpm for 10 min at 4 o C, and protein was measured using the bicinchonic acid method (Pierce, Rockford, IL). ) were added to 1.5 mL MethoCult 3434 (1% methylcellulose, 50 ng/mL mouse SCF, 10 ng/mL IL-3, 20 ng/mL IL-6, and 3 units/mL Epo, 15% FBS, 1% BSA, 10µg/mL bovine pancreatic insulin, 200µg/mL human transferrin, 100 µM β-mercaptoethanol in iMDM). For single cytokine-mediated colony assays, the cells were mixed with 1.5 mL MethoCult 3234 supplemented with either 20 ng/mL mouse SCF, 60 ng/mL G-CSF, 20 ng/mL GM-CSF, 10 ng/mL mouse IL-3, or 20 ng/mL IL-7. In order to promote committed progenitor colonies, G-CSF and SCF were used for progenitors of granulocyte, Epo and SCF for erythrocytes, and Tpo, IL-3, and IL-6 for megakaryocytes. Assays were performed in 35-mm petri dishes. The cells were cultured at 37 o C, in a humidified atmosphere of 5% CO 2 in air.
Colony-forming assays
Colonies were scored as clusters containing more than 50 cells. Cells were then stained in the dish overnight at 37 °C, 5% CO 2 with 2 mL of 0.05% nitro blue tetrazolium (NBT) in PBS, followed by fixing with 4% formaldehyde. The colony size was recorded by digital camera.
Cell proliferation assay
Thymus T cell proliferation was performed using BrdU Cell Proliferation Assay Kit (Roche Molecular Biochemicals, Indianapolis, IN) as directed by manufacturer. Briefly, thymus T cells were suspended in RPMI 1640, 10% FBS with 5 µg/mL Concanavalin A (Con A), or both IL-2 (2 ng/mL) and ConA (5 µg/mL), or RPMI complete medium without cytokine and mitogen, respectively. One hundred µL of the cell suspension (10 6 cells/mL) were grown in a 96-well tissue culture plate in triplicate at 37 o C, 5% CO 2 . Two days later, 10 µL of BrdU (100 µM) was added to each well and incubated for 4 h. The plates were centrifuged at 1200 rpm for 10 min, and heated at 60 o C for 60 min. Cells were fixed with Fixton for 30 min. Incorporated BrdU was detected using HRP-conjugated anti-BrdU specific antibody and HRP substrate, and OD 370 nm was measured in an ELISA reader.
Apoptosis assay
Apoptosis of neutrophils was detected by the TUNEL method using the ApoAlert DNA fragmentation assay kit (Clontech, Palo Alto, CA). Neutrophils were isolated from mouse blood (collected by heart puncture) by treatment with dextran and centrifugation through FicollHypaque. 19 The cells were incubated in RPMI complete medium supplemented with 60 ng/mL mouse G-CSF, and harvested after 20 and 44 h. Cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton X-100, and transferred to glass slides by cytospin. Neutrophils were stained with biotin-labeled anti-Gr-1 and rhodamine-labeled streptavidin, and then reacted with TdT enzyme and nucleotide mix. Apoptotic neutrophils were counted under the fluorescent microscope (total of 1000 Gr-1 positive cells per slide).
Cell lineage analysis by flow cytometry
Blood, bone marrow, spleen, and fetal liver cells were collected as described above. 
Induced granulocytosis by G-CSF treatment
Male 9-10 week-old mice were used in the reported study. Human rG-CSF was injected subcutaneously into both PLSCR1 -/-(n=5) and wild type mice (n=5) at doses of 120 µg/kg/day in approximately 230 µL of saline. G-CSF was administered daily for 5 consecutive days. Blood samples were collected by eye puncture before, and 18, 66, and 114 hours after the initial G-CSF injection. WBC were counted, blood smears were prepared, and differential counts performed (see above).
Statistics
Statistical comparisons were made using the unpaired bilateral Student's t test. Results are expressed as mean ± SD.
For
RESULTS
Mice deficient in PLSCR1
Targeted disruption of the PLSCR1 gene locus and elimination of PLSCR1 protein expression in bone marrow cells of the targeted PLSCR1-/-mice was confirmed by Southern, Northern, and Western blotting (Figure 1 ).
Fig. 1
Similar results were obtained in Northern and Western blots of embryonic fibroblasts, peripheral blood cells and various tissues derived from these animals using the murine PLSCR1-reactive mab 219.1 and rabbit antibody specific for either N-terminal or C-terminal peptides of murine
PLSCR1 (data not shown).
The PLSCR1-/-mice exhibited normal fecundity and litter sizes, normal longevity, and exhibited no obvious phenotypic abnormality (data not shown). Evaluation of peripheral blood cell counts revealed no significant differences between WT and PLSCR1-/-animals ( Table 1) on transbilayer distribution of plasma membrane PLs. 1, 20 This transbilayer "scrambling" of plasma membrane PLs is believed to be responsible for the de novo exposure of PS and other inner leaflet aminophospholipids on the surface of activated platelets and injured or apoptotic cells, and thereby promotes thrombin generation, fibrin clotting, and cell clearance. 21, 22 A selective defect in this plasma membrane PL scramblase pathway is associated with Scott syndrome, an autosomal recessive bleeding disorder. 23 We therefore evaluated the capacity of PLSCR1-/-platelets and erythrocytes to mobilize cell surface PS and to promote hemostasis. We detected no evidence of defective platelet function, nor impaired mobilization of cell surface PS in platelets or erythrocytes obtained from PLSCR1-/-animals (Figures 2 & 3) . 
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These mice also showed no apparent hemostatic abnormality, with tail bleeding times of 98 ±30 sec in PLSCR-/-mice, versus 82 ± 36 sec in WT mice, respectively (mean ± SD determined in ], we cannot exclude the possibility that these negative results for the PLSCR1 knockout is related to the redundancy of expression of PLSCR3, a homologous protein that is also highly expressed in these and other blood cells.
3,22
Evidence for reduced granulocyte production in newborn PLSCR1-/-mice As previously noted, PLSCR1 is a highly interferon-induced gene that has recently been shown to be a substrate of several protein kinases implicated in regulating cell proliferative, differentiation, and apoptotic responses. [4] [5] [6] 10, 14 Furthermore, it has been reported in yeast that whereas knockout of the orthologous gene (YJR100C) yields viable cells, expression of YJR100C in WT yeast cells is up-regulated under several conditions of environmental stress. 13, 24 We therefore considered the possibility that the deletion of PLSCR1 might give rise to phenotypic changes that only become apparent under conditions of stimulated cell proliferation, and might not be manifest in the unchallenged adult animal. In order to explore this possibility, we evaluated hematopoiesis in fetal and newborn animals, a period of rapid clonal expansion under cytokine stimulation. As shown in Table 2 , neutrophil counts in the peripheral blood of newborn PLSCR1-/-and PLSCR1+/-mice were distinctly reduced relative to matched WT animals. This decrease in blood leukocytes at birth was accompanied by a comparable decrease in the relative number of Gr-1 positive cells detected in livers of 2-week old fetuses (Figure 4) .
Defective response to SCF and G-CSF in cultured PLSCR1-/-hematopoietic precursor cells
In order to gain further insight into the origin of this small but significant myeloid deficiency detected in the fetal and newborn PLSCR1-/-animals, we next evaluated cytokine-supported colony formation using hematopoietic precursor cells derived from fetal liver, and from the For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From spleens or bone marrows of age-matched adult animals ( Figure 5 ).
As these data indicate, the hematopoietic precursor cells derived from PLSCR1-/-animals showed a consistent and selective defect in colony formation under stimulation by G-CSF or SCF, an effect that was reproduced using cells derived from all three hematopoietic compartments. In all cases, we observed both a decrease in detectable colony number and in colony size arising from the PLSCR1-/-cells in response to stimulation by G-CSF or SCF, implying both reduced numbers of responsive hematopoietic precursors and reduced cell proliferation under stimulation by these cytokines. By contrast, no obvious differences in cell colony formation from PLSCR1-/-versus WT cells were detected under stimulation by IL-3, IL-7, or GM-CSF, nor were any differences detected when Tpo or Epo were used to promote expansion of megakaryocytic or erythroid colonies.
When cultured in the presence of G-CSF and SCF, hematopoietic precursor cells derived from PLSCR1-/-animals showed distinctly fewer resulting mature granulocytes and a higher proportion of immature cells than identically treated cultures of WT cells ( Figure 6 ; Table 3 ).
For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From These data imply that gene deletion of PLSCR1 affects both hematopoietic precursor cell proliferation ( Figure 5 ) and maturation ( Figure 6 ; Table 3 ) as selectively regulated through these two cytokines.
PLSCR1-/-mice show reduced granulocytosis when treated with G-CSF
We next determined whether the aberrant response to G-CSF stimulation observed for PLSCR1-/-hematopoietic precursor cells when cultured in vitro was also reflected in the myeloproliferative response of the PLSCR1-/-mice to in vivo challenge with this cytokine. Ageand sex-matched WT and PLSCR1-/-animals were injected daily with recombinant human G-CSF, and blood neutrophil counts determined (Figure 7 ).
WT mice responded to G-CSF with a rapid increase in blood neutrophils, reaching 10-fold basal levels at 114 hrs. By contrast, in the PLSCR1-/-mice the response to G-CSF was distinctly delayed and depressed, with blood neutrophils increasing to less than 4-fold basal levels at 114 hrs. Examination of the leukocytes in peripheral blood smears obtained from the mice after G-CSF administration revealed a small increase in the percentage of immature myeloid precursors (predominantly, myelocytes, and bands) in the PLSCR1-/-mice, compared to WT (data not shown). This is consistent with the impaired maturation of granulocytes that was observed upon in vitro culture of the PLSCR1-/-hematopoietic precursors under G-CSF stimulation ( Figure 6 ; Table 3 ). In order to determine whether the decreased granulocytosis observed in the PLSCR1-/-mice was related to an inherently depressed proliferative response to cytokine stimulation, or, to increased tendency of the PLSCR1-/-cells to subsequently undergo apoptosis, we evaluated the spontaneous apoptosis of neutrophils derived from these animals during short-term culture in the presence of G-CSF. We observed no difference in either the rate or extent of apoptosis of PLSCR1-/-neutrophils relative to WT under these conditions. Similarly, no difference in the rate or extent of apoptosis was observed when we compared WT and PLSCR1-/-T-lymphocytes cultured in Con A and IL-2 (data not shown). These results suggest that cellular PLSCR1 promotes neutrophil production by augmenting the proliferative and differentiation responses of myeloid hematopoietic progenitors to stimulation by G-CSF.
PLSCR1 expression is induced by select hematopoietic growth factors
Expression of PLSCR1 is known to be highly induced by both type I & II interferons, a response dependent upon Stat-1 and a single ISRE located in the first untranslated exon of the PLSCR1 gene. 10, 14 The depressed response to certain hematopoietic growth factors observed for cells derived from the PLSCR1-/-mice raised the possibility that PLSCR1 itself normally participates in the cascade of events underlying growth factor-stimulated cellular proliferation and differentiation, and led us to consider whether this response might also include a cytokine-induced increase in PLSCR1 expression. As shown in Figure 8 , G-CSF and SCF each induced a marked increase in the cellular content of PLSCR1. These results are consistent with a role for newly synthesized PLSCR1 in an effector pathway mediating the cellular response to these Fig. 8 cytokines. By contrast to the increased expression of PLSCR1 in WT bone marrow cells observed in response to G-CSF and SCF, there was no apparent change in PLSCR1 levels in response to culture in either TPO or EPO (data not shown).
DISCUSSION
The results of these experiments provide the first direct evidence that the expression of PLSCR1, and potentially other members of the PLSCR gene family, can influence the proliferative and differentiation response of cells to cytokine stimulation, which in the case of murine hematopoietic precursors, selectively affects granulocyte production as stimulated by SCF and G-CSF. These data add to the growing body of evidence that PLSCR1 functions in signaling or effector pathways potentially involved with cell proliferation, differentiation, or apoptosis,
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presumably through its interaction with the various intracellular kinases that have been reported to phosphorylate this protein. [4] [5] [6] It is interesting to note that despite the attenuated myeloid colony growth in response to both SCF and G-CSF observed for PLSCR1-/-cells, the untreated adult PLSCR1-/-mice show no evidence of a relative granulocytopenia, implying complete compensation under normal conditions. Presumably, such compensation in vivo reflects the normal proliferative responses we observed when the PLSCR1-/-hematopoietic precursor cells were stimulated by other cytokines promoting myeloid expansion, in particular IL-3 and GM-CSF.
Our data also indicate that PLSCR1, despite its putative identification as plasma membrane PL scramblase, is not required for normal movement of PS from inner to outer leaflet of the plasma membrane under conditions of either receptor-initiated platelet activation, or direct elevation of intracellular Ca
2+
. As previously reported, we also found that both the mRNA sequence and level of protein expression of PLSCR1 in blood cells obtained from a patient with Scott syndrome were identical to that of normal controls, implying that this bleeding disorder that was shown to reflect diminished function of the PL scramblase pathway in platelets and other blood cells does not reflect either deficiency or defect in PLSCR1. 15 Together with the results of the current experiments, these data imply that PLSCR1 may not function in the plasma membrane PL scramblase pathway as was presumed, although we cannot exclude the possibility that PLSCR1 provides redundant function with another member of the PLSCR gene family in mediating this activity. Of the four PLSCR genes that have been identified in man and mouse, only PLSCR1 and PLSCR3 are readily detected in blood and bone marrow. PLSCR3 shares 47% identity with PLSCR1.
PLSCR1-/-mice did not reveal any difference in the level of expression of PLSCR3 antigen from that detected in WT, implying that there is no compensatory upregulation of PLSCR3 gene expression in the PLSCR1-/-knockout (unpublished data). Like the other members of this gene family, the biologic function of PLSCR3 remains unresolved.
The mechanism by which PLSCR1 affects cell proliferative and differentiation responses to select growth factors remains to be determined. Of particular interest are previous observations that PLSCR1 is the substrate of kinases implicated to participate in regulation of growth, differentiation, and apoptosis, including PKCδ, c-Abl, and unknown kinase(s) activated through cell surface IgE receptors and EGF receptors. [4] [5] [6] [7] In the case of c-Abl, it is known that this interaction with PLSCR1 entails binding of the c-Abl SH3 domain to a proline-rich segment within the N-terminal portion of PLSCR1, and that phosphorylation occurs at two residues (Tyr 69 , Tyr 74 in human PLSCR1) also found within this segment of the polypeptide. 6 As noted above, a spontaneous deletion of the corresponding portion of murine PLSCR1 that was identified in clones derived from the MM cell line has been implicated in their leukemogenic transformation, which also suggests a possible role of PLSCR1 in the normal regulation of cytokine-dependent proliferation and differentiation responses.
11
The defective proliferation and differentiation of PLSCR1-/-hematopoietic precursors when stimulated by SCF or G-CSF, but not the other cytokines tested, implies that PLSCR1 plays a selective role in either the signaling or effector pathways initiated through the c-kit and G-CSF receptors (G-CSFR). Stimulation of c-kit or G-CSFR initiates multiple intracellular signaling events leading to nuclear transcription, which utilize enzymes, adaptor proteins, and transcription factors that are both common to, and divergent from, those recruited by other activated growth For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From factor receptors. [25] [26] [27] Comparison of the known downstream signaling events that are common to both c-kit and G-CSFR, to those initiated by the other growth factor receptors that appear to normally function in PLSCR1-/-cells (e.g., IL3R and GM-CSFR), does not provide an obvious explanation for why the response to SCF and G-CSF might be selectively impaired in cells genetically deficient in PLSCR1. On the other hand, the observation that the expression of PLSCR1 is also markedly induced following stimulation by SCF and G-CSF in the WT cells, suggests that PLSCR1 contributes to the cellular response to these cytokines through a posttranscriptional effector pathway(s) underlying subsequent colony expansion and differentiation.
Insight into how increased cellular content of PLSCR1 might serve to promote proliferation and differentiation of myeloid-committed cells as stimulated by SCF and G-CSF, and its potential contribution to other growth factor receptor regulated responses, awaits further clarification of the precise intracellular function(s) of PLSCR1 and other members of this unique gene family. Differential cell counts were obtained on Wright-Giemsa smears described in Figure 6 . A total of 500 cells were evaluated in each slide, and percent of each cell type determined. *Other cells include monocytes, plasma cells, and lymphocytes. Neutrophil counts were derived from whole blood WBC counts and WBC differential counts. **P < 0.01 compared to wild type. 
